SEC Comment Letter 0000000000-25-003058 to NEKTAR THERAPEUTICS (NKTR)

NEKTAR THERAPEUTICS
Date: March 20, 2025 · CIK: 0000906709 · Accession: 0000000000-25-003058

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

March 20, 2025

Author

Division of

Form

UPLOAD

Company

NEKTAR THERAPEUTICS

Letter

Re: Nektar Therapeutics Draft Registration Statement on Form S-3 Submitted March 14, 2025 CIK No. 0000906709 Dear Howard Robin:

March 20, 2025

Howard Robin Chief Executive Officer Nektar Therapeutics 455 Mission Bay Boulevard South San Francisco, CA 94158

This is to advise you that we do not intend to review your registration statement.

We request that you publicly file your registration statement no later than two business days prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Justin Platt

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 March 20, 2025

Howard Robin
Chief Executive Officer
Nektar Therapeutics
455 Mission Bay Boulevard South
San Francisco, CA 94158

 Re: Nektar Therapeutics
 Draft Registration Statement on Form S-3
 Submitted March 14, 2025
 CIK No. 0000906709
Dear Howard Robin:

 This is to advise you that we do not intend to review your registration
statement.

 We request that you publicly file your registration statement no later
than two
business days prior to the requested effective date and time. Please refer to
Rules 460 and 461
regarding requests for acceleration. We remind you that the company and its
management are
responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review,
comments, action or absence of action by the staff.

 Please contact Lauren Hamill at 303-844-1008 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Justin Platt
</TEXT>
</DOCUMENT>

SecProbe.io